Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Novo Nordisk Invests $2B to Expand API Manufacturing in Denmark | Contract Pharma

What are you searching for?

Sign in
Breaking News

Novo Nordisk Invests $2B to Expand API Manufacturing in Denmark

New facility will create additional production capacity to support future market demand for its late-phase product portfolio.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Novo Nordisk will invest $2 billion starting in 2023 to expand an existing Active Pharmaceutical Ingredient (API) production facility in Hillerød, Denmark to support its future portfolio in serious chronic diseases.

The facility will create additional production capacity and increase its ability to meet future market demands for its late-phase product portfolio. Construction is underway and the facility is expected to start producing API by early 2029. The project is expected to create 340 new jobs when construction is completed.

The new 65,000 square-meter facility will be designed as a multi-product facility, with maximum flexibility to accommodate new processes and displaying state-of-the-art technology and working environment.

“This important investment will ensure the continuous development of our late-phase pipeline into deliveries of important medicines for treatments to patients worldwide,” said Henrik Wulff, executive vice president of Product Supply, Quality & IT.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics